>
AllerMAbsAllerMAbs
艾樂(lè)美生物科技有限公司(AllerMAbs Co., Ltd.)成立于2015年,是臺(tái)灣一家專注于生產(chǎn)高親和力、高純度并具有過(guò)敏原特異性的嵌合人類IgE單克隆抗體的生物公司。
AllerMAbs的產(chǎn)品解決了目前人類IgE抗體不易制備的問(wèn)題,讓嵌合人類IgE抗體可以成為人類IgE抗體的替代品,并提供一個(gè)更穩(wěn)定、更符合血清IgE檢測(cè)系統(tǒng)的校正品,讓臨床血清IgE的檢測(cè)結(jié)果更加準(zhǔn)確與可靠。
其利用動(dòng)物基因轉(zhuǎn)殖技術(shù),將組成人類IgE抗體分子的ε重鏈(Heavy chain)和κ輕鏈(Light chain)的編碼基因(Encoding genes),分別嵌入(Knock-in)小鼠胚胎干細(xì)胞(Embryonic stem cells, ES cells)的γ1重鏈和κ輕鏈基因的位置,接著把胚胎干細(xì)胞分別植入孕母鼠體內(nèi),并將其帶有嵌入基因之成鼠交互配種,最后得到帶有人類IgE抗體重鏈和輕鏈基因的基因嵌入小鼠(HεκKI mice),且體內(nèi)能制造完整的嵌合人類IgE抗體分子。
Allermabs is a prevalent disease in both developed and developing countries. IgE plays a major role in allergic diseases despite its low expression in the body. Understanding the relationship between IgE responses and clinical symptoms as well as advancing the IgE detection techniques will significantly improve disease management. However, pure IgE is rare and expensive, which may hamper research and assay development. IgE mAbs, allergen-specific human IgE mAbs in particular, are also very difficult to prepare either by hybridoma or recombinant DNA technologies. These obstacles limit the supply of IgE mAbs on the market. Thus, new technology to produce large quantity and high quality of human IgE mAbs or their equivalents are urgently needed to improve both basic IgE research as well as clinical applications. We have designed a proprietary transgenic mouse in conjunction with hybridoma technologies by which the preparation of IgE hybridomas is more practical and the production of allergen-specific chimeric human IgE is very efficient. These transgenic mice can be immunized to induce the B cell proliferation to overcome the limitation of low numbers of human IgE B cells obtained for making IgE hybridomas. Using allergen-immunized transgenic mice to prepare IgE hybridomas producing allergen-specific chimeric human IgE is also a leading platform in IgE research and production.
Our research team has been studying human IgE and developing antibody production techniques at the Academia Sinica in Taiwan since 2009. We have designed transgenic animals expressing human IgE genes and utilized these animal models to produce IgE mAbs. Recently, we developed a gene knock-in mouse model capable of producing chimeric human IgE antibodies. Using hybridoma technologies, we successfully prepared IgE hybridomas producing allergen-specific chimeric human IgE mAbs and purified the mAbs by affinity chromatography. Our analyses showed that the chimeric human IgE antibodies generated from our system exhibited equivalent biochemical and biological properties to human IgE. To systematically generate large scale of various chimeric human IgE mAbs, we founded AllerMAbs Co., Ltd. and signed an exclusive patent license contract with Academia Sinica. Currently, we are generating chimeric human IgE mAbs specifically reactive towards different allergen components in large scale.
產(chǎn)品列表:
AllerMAbs |
DP120H4 |
Monoclonal Anti-Der p 1 Chimeric Human IgE |
50 μg |
AllerMAbs |
DP120H4 |
Monoclonal Anti-Der p 1 Chimeric Human IgE |
100 μg |
AllerMAbs |
DP120H4 |
Monoclonal Anti-Der p 1 Chimeric Human IgE |
200 μg |
AllerMAbs |
DP120H4 |
Monoclonal Anti-Der p 1 Chimeric Human IgE |
500 μg |
AllerMAbs |
DP120H4 |
Monoclonal Anti-Der p 1 Chimeric Human IgE |
1 mg |
AllerMAbs |
DP238F9 |
Monoclonal Anti-Der p 2 Chimeric Human IgE |
50 μg |
AllerMAbs |
DP238F9 |
Monoclonal Anti-Der p 2 Chimeric Human IgE |
100 μg |
AllerMAbs |
DP238F9 |
Monoclonal Anti-Der p 2 Chimeric Human IgE |
200 μg |
AllerMAbs |
DP238F9 |
Monoclonal Anti-Der p 2 Chimeric Human IgE |
500 μg |
AllerMAbs |
DP238F9 |
Monoclonal Anti-Der p 2 Chimeric Human IgE |
1 mg |
AllerMAbs |
BV117G2 |
Monoclonal Anti-Bet v 1 Chimeric Human IgE |
50 μg |
AllerMAbs |
BV117G2 |
Monoclonal Anti-Bet v 1 Chimeric Human IgE |
100 μg |
AllerMAbs |
BV117G2 |
Monoclonal Anti-Bet v 1 Chimeric Human IgE |
200 μg |
AllerMAbs |
BV117G2 |
Monoclonal Anti-Bet v 1 Chimeric Human IgE |
500 μg |
AllerMAbs |
BV117G2 |
Monoclonal Anti-Bet v 1 Chimeric Human IgE |
1 mg |
AllerMAbs |
OVA8G9 |
Monoclonal Anti-Ovalbumin Chimeric Human IgE |
50 μg |
AllerMAbs |
OVA8G9 |
Monoclonal Anti-Ovalbumin Chimeric Human IgE |
100 μg |
AllerMAbs |
OVA8G9 |
Monoclonal Anti-Ovalbumin Chimeric Human IgE |
200 μg |
AllerMAbs |
OVA8G9 |
Monoclonal Anti-Ovalbumin Chimeric Human IgE |
500 μg |
AllerMAbs |
OVA8G9 |
Monoclonal Anti-Ovalbumin Chimeric Human IgE |
1 mg |
AllerMAbs |
PAP1C6 |
Monoclonal Anti-Papain Chimeric Human IgE |
50 μg |
AllerMAbs |
PAP1C6 |
Monoclonal Anti-Papain Chimeric Human IgE |
100 μg |
AllerMAbs |
PAP1C6 |
Monoclonal Anti-Papain Chimeric Human IgE |
200 μg |
AllerMAbs |
PAP1C6 |
Monoclonal Anti-Papain Chimeric Human IgE |
500 μg |
AllerMAbs |
PAP1C6 |
Monoclonal Anti-Papain Chimeric Human IgE |
1 mg |
AllerMAbs |
CAS11A2 |
Monoclonal Anti-Casein Chimeric Human IgE |
50 μg |
AllerMAbs |
CAS11A2 |
Monoclonal Anti-Casein Chimeric Human IgE |
100 μg |
AllerMAbs |
CAS11A2 |
Monoclonal Anti-Casein Chimeric Human IgE |
200 μg |
AllerMAbs |
CAS11A2 |
Monoclonal Anti-Casein Chimeric Human IgE |
500 μg |
AllerMAbs |
CAS11A2 |
Monoclonal Anti-Casein Chimeric Human IgE |
1 mg |
AllerMAbs |
NON29C11 |
Monoclonal Chimeric Human IgE Control |
100 μg |
AllerMAbs |
NON29C11 |
Monoclonal Chimeric Human IgE Control |
500 μg |
AllerMAbs |
NON29C11 |
Monoclonal Chimeric Human IgE Control |
1 mg |
AllerMAbs |
NON29C11 |
Monoclonal Chimeric Human IgE Control |
5 mg |
AllerMAbs |
NON29C11 |
Monoclonal Chimeric Human IgE Control |
10 mg |